(RTTNews) - Halozyme Therapeutics (HALO) announced that Takeda received regulatory approval for HYQVIA by the Japanese Ministry of Health, Labour and Welfare for patients with agammaglobulinemia or hypogammaglobulinemia. HYQVIA is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10% and one vial of Recombinant Human Hyaluronidase PH20, which is Halozyme's ENHANZE drug delivery technology.
"We are very pleased that patients in Japan with agammaglobulinemia or hypogammaglobulinemia can now access HYQVIA, which represents the first and only subcutaneous immunoglobulin therapy that offers the potential of a reduced dosing frequency," said Helen Torley, CEO of Halozyme.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
